Katherine Peisochenske, PA
Physician Assistant · Newark, DENPI 1588815195
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Livanova USA, Inc. at 46.1% of the total. 2025 is the largest year on record at $1,303, 2.9 times the $448 reported in 2021. Among physician assistant clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 86 payments — averaging $50.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$2K
- Medtronic$906
- AbbVie$359
- UCB, Inc.$228
- Abbott$142
- Harmony Biosciences LLC$130
- plus $589 from 9 others
What the payments were for
- Speaking & faculty fees$231%
- Travel & lodging$1,73140%
- Food & beverage$2,60960%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 15 | $2,009 |
| Medtronic | 9 | $906 |
| AbbVie | 22 | $359 |
| UCB, Inc. | 8 | $228 |
| Abbott | 1 | $142 |
| Harmony Biosciences LLC | 5 | $130 |
| Jazz Pharmaceuticals Inc. | 6 | $123 |
| Acorda Therapeutics, Inc | 6 | $118 |
| Amneal Pharmaceuticals LLC | 5 | $104 |
| Neurocrine Biosciences, Inc. | 1 | $94 |
| Avanir Pharmaceuticals, Inc. | 3 | $47 |
| MDD US Operations, LLC | 1 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Upsher-smith Laboratories LLC | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,839
- ACTIVA PC$717
- INFINITY$142
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$101
How this compares
$4,363 in reported general payments places this provider in the 95th percentile of 527 physician assistant providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 42 | $211,070 |
| IngrezzaValbenazine Tosylate | 21 | $171,610 |
| EpidiolexCannabidiol (Cbd) | 12 | $92,270 |
| AustedoDeutetrabenazine | 16 | $82,603 |
| RytaryCarbidopa/Levodopa | 43 | $62,147 |
| BriviactBrivaracetam | 33 | $58,345 |
| XcopriCenobamate | 37 | $52,033 |
| GocovriAmantadine Hcl | 12 | $40,392 |
| Oxtellar XrOxcarbazepine | 16 | $32,903 |
| NayzilamMidazolam | 38 | $28,676 |
| Topiramate ErTopiramate | 11 | $23,373 |
| Clobazam | 80 | $20,000 |
| FycompaPerampanel | 13 | $19,562 |
| Lacosamide | 173 | $18,757 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 346 | $14,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $94 | $171,61021 claims |
| UCB, Inc.Briviact, Nayzilam | $228 | $87,02171 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $29 | $82,60316 claims |
| Amneal Pharmaceuticals LLCRytary | $104 | $62,14743 claims |
| MDD US Operations, LLCGocovri | $31 | $40,39212 claims |
| Upsher-smith Laboratories LLCTopiramate | $22 | $1,20194 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 527 physician assistant providers in Delaware.
Other physician assistant in Newark
- Vi BanhNewark$12K
- Alexandra KrochtaNewark$9K
- Seth CallahanNewark$7K
- Nicole Wotus-SilvestriNewark$7K
- Kalyn MozulayNewark$5K
- Emma Ellman-GrovesNewark$4K
- Victoria AtchisonNewark$4K
- Shakara SmithNewark$3K
- Aimee FongNewark$3K
- Daniella BensonNewark$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.